Here's Why You Should Avoid Amwell Stock Right Now

The coronavirus pandemic has been a huge boost to the popularity of telehealth services, and that popularity has been spilling over into the stock market. In September, Amwell (NYSE: AMWL) raised around $742 million in a successful initial public offering (IPO) from investors excited about the company's telehealth platform.

In this recently aired Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Cory Renauer talk about Amwell's recent IPO and potential competition with Teladoc Health (NYSE: TDOC). Press play to hear them discuss why Amwell might not be a stock you want in your portfolio.

Source Fool.com